Tag Archive for: RNA

Claudia Ulbrich, MD, CEO und Prof. Thomas Thum, MD, PhD, CSO/CMO at Cardior Pharmaceuticals. © Cardior Pharmaceuticals

Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.

Primary astrocyte cells. © Dr Eva Latorre, Harries lab/Senisca Ltd

Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.

© Stephanie Kath-Schorr

German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.

© SynaptixBio Ltd

Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.

Amplys team around CEO Ben Thomas (4th from left). © Amply Discovery Ltd

Belfast-based techbio company AMPLY Discovery Ltd announced today will make use of a £1.4m in grant funding to advance its AI-based drug discovery platform.

© MikeMareen

To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products

Boehringer Ingelheim headquarters. © Boehringer Ingelheim

Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from  Kyowa Kirin Co. Ltd.

Brown and white fat cells. © Patrick Seale, University of Pennsylvania School of Medicine/NIH

Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.

© MikeMareen

Dyadic International Inc. and bYoRNA SAS partnered to advance innovative bioproduction technologies for scaling up the production of therapeutic mRNA from C1-Cells.

Alnylam CEO Yvonne-Greenstreet. © Alnylam Pharmaceuticals.jpg

siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T